Table 1.
Demographics and baseline characteristics
| Treatment arm |
|||
|---|---|---|---|
| Total (n = 118) | Placebo (n = 28) | VCV (n = 90) | |
| Gender | |||
| Male | 108 (92%) | 26 (93%) | 82 (91%) |
| Female | 10 (8%) | 2 (7%) | 8 (9%) |
| Race/ethnicity | |||
| White | 77 (65%) | 21 (75%) | 56 (62%) |
| Black | 24 (20%) | 5 (18%) | 19 (21%) |
| Hispanic | 14 (12%) | 1 (4%) | 13 (14%) |
| Other | 3 (3%) | 1 (4%) | 2 (2%) |
| Age, years | |||
| Median | 46 | 48 | 46 |
| 13–29 | 1 (1%) | 0 (0%) | 1 (1%) |
| 30–39 | 15 (13%) | 5 (18%) | 10 (11%) |
| 40–49 | 58 (49%) | 12 (43%) | 46 (51%) |
| 50–59 | 32 (27%) | 10 (36%) | 22 (24%) |
| ≥60 | 12 (10%) | 1 (4%) | 11 (12%) |
| IV drug history | |||
| Never | 113 (96%) | 27 (96%) | 86 (96%) |
| Previously | 5 (4%) | 1 (4%) | 4 (4%) |
| CD4 count, cells/mm3 | |||
| Median (Q1, Q3) | 139 (60, 265) | 163 (66, 228) | 127 (53, 278) |
| Log (HIV-1 RNA), copies/mL | |||
| Median (Q1, Q3) | 4.58 (4.17, 5.04) | 4.38 (4.04, 4.66) | 4.65 (4.19, 5.23) |
| Baseline neurotoxic nucleoside RTIa use | 49 (42%) | 11 (39%) | 38 (42%) |
| Day 14 neurotoxic nucleoside RTIa use | 32 (27%) | 8 (29%) | 24 (27%) |
Note: VCV = vicriviroc; RTI = reverse transcriptase inhibitor.
a
didanosine, stavudine, zalcitabine